Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that Ankur
Dhingra has been appointed as Chief Financial Officer,
effective immediately.
“We are in a pivotal time for Team Summit as we
seek to expand our portfolio of pipeline assets through potential
collaborations and possible acquisitions,” said Robert W. Duggan,
Chairman and Chief Executive Officer of Summit. “Ankur’s leadership
and experience will be critical in ensuring the financial viability
and excellence of our organization. Ankur’s wealth of knowledge
across all aspects of finance will add substantial value to our
organization as we take the next step in seeking to make a
significant difference for the betterment of overall human
health. We are truly pleased to welcome Ankur to Team
Summit.”
Mr. Dhingra most recently served as the CFO of
CAREDx, Inc. (NASDAQ: CDNA), and has over 20 years of experience in
finance across life sciences and technology. In his role at CAREDx,
Mr. Dhingra was responsible for all finance functions in addition
to market access and information technology. Prior to his
time at CAREDx, Mr. Dhingra spent over 15 years at Agilent
Technologies holding positions of increasing responsibility across
its finance organization, including serving in multiple business
unit CFO roles. Mr. Dhingra has demonstrated a track record of
success scaling businesses by executing and influencing
growth-oriented business strategies. He has extensive experience
managing global teams of finance and accounting professionals. Mr.
Dhingra is a member of the Institute of Chartered Accountants of
India.
“I am excited to join Team Summit and its
impressive leadership team,” stated Mr. Dhingra. “Summit’s mission
to develop, gain approval, and commercialize its medicinal
therapies – whether through discovery or business development
opportunities – in order to meaningfully improve the quality and
potential duration of patients’ lives is truly inspirational. I
look forward to the opportunity to help build and scale a superior
business that seeks to optimize human health.”
In addition to managing Summit’s finance
function, Mr. Dhingra will also be responsible for the information
technology and human resources functions.
Summit Therapeutics’ Mission
StatementTo build a viable, long-lasting health care
organization that assumes full responsibility for designing,
developing, trial execution and enrollment, regulatory submission
and approval, and successful commercialization of patient,
physician, caregiver, and societal-friendly medicinal therapy
intended to: improve quality of life, increase potential
duration of life, and resolve serious medical healthcare needs. To
identify and control promising product candidates based on
exceptional scientific development and administrational expertise,
develop our products in a rapid, cost-efficient manner, and to
engage commercialization and/or development partners when
appropriate.
We accomplish this by building a team of world
class professional scientists and business administrators that
apply their experience and knowledge to this mission. Team Summit
exists to pose, strategize, and execute a path forward in medicinal
therapeutic health care that places Summit in a well-deserved, top
market share, leadership position. Team Summit assumes full
responsibility for stimulating continuous expansion of knowledge,
ability, capability, and well-being for all involved stakeholders
and highly-valued shareholders.
About Summit TherapeuticsSummit
was founded in 2003 and our shares are listed on the Nasdaq Global
Market (symbol ‘SMMT’). We are headquartered in Cambridge,
Massachusetts, and we have additional offices in Oxford, UK,
Cambridge, UK, and Menlo Park, California.
For more information, please visit
https://www.summittxinc.com and follow us on Twitter
@summitplc.
Contact Summit Investor Relations:
Dave GancarzHead of Stakeholder Relations &
Corporate Strategydavid.gancarz@summitplc.com
General Inquiries:
investors@summitplc.com
Summit Forward-looking Statements
Any statements in this press release about the
Company’s future expectations, plans and prospects, including but
not limited to, statements about the clinical and preclinical
development of the Company’s product candidates, the therapeutic
potential of the Company’s product candidates, the potential
commercialization of the Company’s product candidates, the timing
of initiation, completion and availability of data from clinical
trials, the potential submission of applications for marketing
approvals, the impact of the COVID-19 pandemic on the Company’s
operations and clinical trials, potential acquisitions and other
statements containing the words "anticipate," "believe,"
"continue," "could," "estimate," "expect," "intend," "may," "plan,"
"potential," "predict," "project," "should," "target," "would," and
similar expressions, constitute forward-looking statements within
the meaning of The Private Securities Litigation Reform Act of
1995. Actual results may differ materially from those indicated by
such forward-looking statements as a result of various important
factors, including the results of our evaluation of the underlying
data in connection with the topline results of our Phase III
Ri-CoDIFy study evaluating ridinilazole, the outcome of discussions
with regulatory authorities, including the Food and Drug
Administration, the uncertainties inherent in the initiation of
future clinical trials, availability and timing of data from
ongoing and future clinical trials, the results of such trials, and
their success, and global public health crises, including the
coronavirus COVID-19 outbreak, that may affect timing and status of
our clinical trials and operations, whether preliminary results
from a clinical trial will be predictive of the final results of
that trial or whether results of early clinical trials or
preclinical studies will be indicative of the results of later
clinical trials, whether business development opportunities to
expand the Company’s pipeline of drug candidates, including without
limitation, through potential acquisitions of, and/or
collaborations with, other entities occur, expectations for
regulatory approvals, laws and regulations affecting government
contracts and funding awards, availability of funding sufficient
for the Company’s foreseeable and unforeseeable operating expenses
and capital expenditure requirements and other factors discussed in
the "Risk Factors" section of filings that the Company makes with
the Securities and Exchange Commission. Any change to our ongoing
trials could cause delays, affect our future expenses, and add
uncertainty to our commercialization efforts, as well as to affect
the likelihood of the successful completion of clinical development
of ridinilazole. Accordingly, readers should not place undue
reliance on forward-looking statements or information. In addition,
any forward-looking statements included in this press release
represent the Company’s views only as of the date of this release
and should not be relied upon as representing the Company’s views
as of any subsequent date. The Company specifically disclaims any
obligation to update any forward-looking statements included in
this press release.
Summit Therapeutics (NASDAQ:SMMT)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Summit Therapeutics (NASDAQ:SMMT)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024